ReviewVascular health and risk management2007
Reduction of C-reactive protein and the use of anti-hypertensives.
Review in Vascular health and risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Cardiac Biomarkers in Pregnancies With and Without Hypertension.American journal of hypertension · 2025Article
- Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment.Cells · 2024Review
- Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.Nutrients · 2024Review
- New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications.International journal of molecular sciences · 2024Review
- Vascular Aging and Central Aortic Blood Pressure: From Pathophysiology to Treatment.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Review
- First-line treatment of essential hypertension: A real-world analysis across four antihypertensive treatment classes.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Immune signaling mechanisms of PTSD risk and symptom development: insights from animal models.Current opinion in behavioral sciences · 2017Article
- Activation of angiotensin II type 2 receptor suppresses TNF-α-induced ICAM-1 via NF-кB: possible role of ACE2.American journal of physiology. Heart and circulatory physiology · 2015Article
- Analysis of inflammatory mediators in type 2 diabetes patients.International journal of endocrinology · 2013Article
- Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte infiltration than males.American journal of physiology. Regulatory, integrative and comparative physiology · 2012Article
- Vascular inflammation and endothelial dysfunction in experimental hypertension.International journal of hypertension · 2011Article
- Identification and treatment of metabolic complications in pediatric obesity.Reviews in endocrine & metabolic disorders · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory processes are increasingly recognized as important participants in the pathophysiology of hypertension and cardiovascular disease. Angiotensin II may be to a large degree responsible for triggering vascular inflammation by inducing oxidative stress, resulting in up-regulation of inflammatory mediators. Inflammatory markers such as C-reactive protein are increased in the blood of patients with hypertension and predict the development of cardiovascular disease. Moreover, C-reactive protein may be a pro-inflammatory molecule under certain circumstances. C-reactive protein and high blood pressure in combination have additional predictive value for cardiovascular outcomes, as they contribute as independent determinants of cardiovascular risk. Therapeutic intervention aimed to reduce vascular inflammation in hypertensive patients has been proposed. Recent lines of evidence suggest that lifestyle modification and pharmacological approaches may reduce blood pressure and inflammation in patients with hypertension. Antagonism of the renin-angiotensin system with the selective angiotensin receptor blockers may improve cardiovascular outcome beyond blood pressure control, by reducing vascular inflammation and remodeling.
Indexed as
Identifiers
18200816PMC2350124W207584000What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.